Targeted therapy using alpha particles for ovarian cancer treatment
Official title: Antibody-based prertargeted alpha particle therapy for ovarian cancer
Funded at Viewpoint Molecular Targeting, INC. · NIH-10821914 · Data updated 2026-11-12
This study is testing a new way to treat high-grade serous ovarian cancer by using a special type of radiation that targets cancer cells directly, hoping to help patients who haven't had success with other treatments feel better and live longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Viewpoint Molecular Targeting, INC. NIH-funded |
| Lab location | 1 site (Coralville, UNITED STATES) |
| Project start | June 5, 2024 |
| Project end | November 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $391,553 |
| NIH project number | 1R42CA287696-01 |
| Project ID | NIH-10821914 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with high-grade serous ovarian carcinoma, particularly those with metastatic disease who have not responded to standard therapies.
✕Less likely to help
Patients with early-stage ovarian cancer or those who have not been diagnosed with high-grade serous ovarian carcinoma may not benefit from this research.
What this research studies
This research focuses on developing a new treatment for high-grade serous ovarian carcinoma (HGSOC), which is a common and aggressive form of ovarian cancer. The approach involves using targeted alpha-particle therapy, which aims to deliver radiation directly to cancer cells while minimizing damage to surrounding healthy tissue. By utilizing advanced imaging techniques and specific targeting of tumor markers, this therapy seeks to improve outcomes for patients who have not responded well to existing treatments. The goal is to enhance survival rates and quality of life for those affected by metastatic HGSOC.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with metastatic ovarian cancer, potentially improving survival rates and reducing recurrence.
How similar studies have gone: Previous research has shown promise with targeted alpha-particle therapies in other cancer types, indicating potential for success in this novel application for ovarian cancer.
Where this research is happening
-
Viewpoint Molecular Targeting, INC.
Coralville, United States Active
Researchers
- Principal investigator: Schultz, Michael King — Viewpoint Molecular Targeting, INC.
- Study coordinator: Schultz, Michael King
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.